Searchable abstracts of presentations at key conferences in endocrinology

ea0038oc3.3 | Steroids and adrenal | SFEBES2015

11β-HSD1-mediated decrease in COX2 expression is abrogated by hypoxia in human dermal fibroblasts

Tiganescu Ana , Wittmann Miriam , Morgan Ann , Stewart Paul

Chronic wounds contribute significantly to patient morbidity, mortality and associated healthcare costs. Glucocorticoid (GC) excess and hypoxia are both associated with impaired wound healing (WH) outcomes. The cyclooxygerase 2 (COX2) pathway is an integral component of inflammation and WH. Locally, GC availability is regulated by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) which generates cortisol from inactive cortisone. Although we recently demon...

ea0077p40 | Metabolism, Obesity and Diabetes | SFEBES2021

A randomised controlled pilot trial of oral 11β-HSD1 inhibitor AZD4017 for wound healing in adults with type 2 diabetes mellitus

Ajjan Ramzi , Hensor Elizabeth , Shams Kave , Galdo Francesco Del , Abbas Afroze , Woods Janet , Fairclough Rebecca , Pegg Lindsay , Freeman Adrian , Morgan Ann , Stewart Paul , Taylor Angela , Arlt Wiebke , Tahrani Abd , Russell David , Tiganescu Ana

Chronic wounds (e.g. diabetic foot ulcers) have a major impact on quality of life, yet treatments remain limited. Glucocorticoids impair wound healing; preclinical research suggests that blocking glucocorticoid activation by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) improves wound repair. This investigator-initiated double-blind, randomised, placebo-controlled parallel-group phase 2b pilot trial investigated efficacy, safety and feasibility of 11&...